IL290101A - Methods for the treatment of antibody-mediated diseases with the help of fcrn antagonists - Google Patents

Methods for the treatment of antibody-mediated diseases with the help of fcrn antagonists

Info

Publication number
IL290101A
IL290101A IL290101A IL29010122A IL290101A IL 290101 A IL290101 A IL 290101A IL 290101 A IL290101 A IL 290101A IL 29010122 A IL29010122 A IL 29010122A IL 290101 A IL290101 A IL 290101A
Authority
IL
Israel
Prior art keywords
methods
mediated disorders
treating antibody
fcrn antagonists
fcrn
Prior art date
Application number
IL290101A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL290101A publication Critical patent/IL290101A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL290101A 2019-07-25 2022-01-24 Methods for the treatment of antibody-mediated diseases with the help of fcrn antagonists IL290101A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Publications (1)

Publication Number Publication Date
IL290101A true IL290101A (en) 2022-03-01

Family

ID=72087159

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290101A IL290101A (en) 2019-07-25 2022-01-24 Methods for the treatment of antibody-mediated diseases with the help of fcrn antagonists

Country Status (13)

Country Link
US (1) US20210024620A1 (enExample)
EP (1) EP4004039A2 (enExample)
JP (2) JP2022542884A (enExample)
KR (1) KR20220038432A (enExample)
CN (1) CN114466663B (enExample)
AU (1) AU2020315925A1 (enExample)
BR (1) BR112022001255A2 (enExample)
CA (1) CA3148764A1 (enExample)
CO (1) CO2022001164A2 (enExample)
IL (1) IL290101A (enExample)
MX (1) MX2022001038A (enExample)
TW (1) TW202120539A (enExample)
WO (1) WO2021016571A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250042176A (ko) 2022-07-27 2025-03-26 아블린쓰 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
CN121443644A (zh) 2023-07-05 2026-01-30 阿布林克斯有限公司 用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂
CN122029191A (zh) 2023-08-23 2026-05-12 赛诺菲 基于ctla-4的溶酶体降解剂及其用途
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025144848A1 (en) * 2023-12-27 2025-07-03 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) * 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR102168731B1 (ko) * 2011-03-30 2020-10-23 추가이 세이야쿠 가부시키가이샤 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SG10201800492PA (en) * 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CA2946430A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
EP3215528B1 (en) * 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
KR102720769B1 (ko) * 2015-03-09 2024-10-22 아르제넥스 비브이 FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CN111094335B (zh) * 2017-05-15 2022-08-23 罗切斯特大学 广泛中和的抗流感单克隆抗体及其用途
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
CA3089602A1 (en) * 2018-01-26 2019-08-01 Genzyme Corporation Fc variants with enhanced binding to fcrn and prolonged half-life

Also Published As

Publication number Publication date
MX2022001038A (es) 2022-04-26
BR112022001255A2 (pt) 2022-06-14
CN114466663A (zh) 2022-05-10
WO2021016571A3 (en) 2021-03-04
AU2020315925A1 (en) 2022-03-03
US20210024620A1 (en) 2021-01-28
JP2022542884A (ja) 2022-10-07
CN114466663B (zh) 2026-01-02
TW202120539A (zh) 2021-06-01
CA3148764A1 (en) 2021-01-28
JP2025098167A (ja) 2025-07-01
CO2022001164A2 (es) 2022-03-08
KR20220038432A (ko) 2022-03-28
WO2021016571A2 (en) 2021-01-28
EP4004039A2 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
IL254403A0 (en) Methods for lowering the amount of fc-containing substances in the serum by using fcrn antibodies
IL267818A (en) Methods for treating neurological disorders
IL267229A (en) Methods of treating ocular disorders
IL269082A (en) Methods for treating lysosomal disorders
SG11202108029XA (en) Methods of treating multiple myeloma
IL256424A (en) Methods for treating autoimmune and alloimmune disorders
IL270114B1 (en) Methods and compounds for the treatment of neurological diseases
IL276358A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF ADDICTION AND RELATED DISORDERS
ZA202002991B (en) Methods and compositions for assessing and treating intraocular diseases and disorders
SG11202103019WA (en) Methods of treating myeloproliferative disorders
GB201907153D0 (en) Methods of treating neuropathy
SG11202105279SA (en) Methods of treating myeloproliferative disorders
IL292678A (en) Methods for treating depressive disorders
IL275985A (en) Preparations and methods for the treatment of retinal disorders
SG11202100962XA (en) Platelet count-agnostic methods of treating myelofibrosis
IL269604A (en) Pentides for the treatment of autoimmune diseases
IL280424A (en) Methods for treating neurodegenerative disorders
SG11202102982QA (en) Methods of treating myeloproliferative disorders
IL290138A (en) Methods of treating diseases associated with elevated levels of antibodies that interact with the nmda receptor
SG11202102240YA (en) Methods of treating psoriasis
HK40075205A (en) Methods of treating antibody-mediated disorders with fcrn antagonists
PL3654965T3 (pl) Sposoby leczenia autoimmunologicznych chorób mikronaczyniowych
IL252151A0 (en) Treatment of stress disorders
IL291639A (en) A method for treating mood disorders